Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 2 boards, counting each seat separately. Longest: Mineralys Therapeutics Inc., 3 years.
Mineralys Therapeutics Inc.
Director
COMPASS Pathways Plc
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Mineralys Therapeutics Inc. May 21, 202699.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Mineralys Therapeutics Inc. | Option exercise | +3,000 | $12.02 | $36,060 |
| Sep 15, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −3,000 | $28.58 | $85,740 |
| Jun 17, 2026 | Mineralys Therapeutics Inc. | Option exercise | +3,000 | $12.02 | $36,060 |
| Jun 17, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −3,000 | $25.00 | $75,000 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Option exercise | +3,000 | $12.02 | $36,060 |
| Mar 31, 2026 | Mineralys Therapeutics Inc. | Open-market sale | −3,000 | $25.00 | $75,000 |
| Feb 19, 2026 | Mineralys Therapeutics Inc. | Grant or award | +6,200 | — | — |
| Nov 13, 2025 | Mineralys Therapeutics Inc. | Option exercise | +15,000 | $10.20 | $153,000 |
| Nov 13, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −10,115 | $45.81 | $463,368 |
| Nov 13, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −4,885 | $46.36 | $226,469 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.